Ombitasvir/paritaprevir/ritonavir/dasabuvir ± ribavirin is safe and effective in HCV-infected patients in a real-life cohort from Latin America.

about

Developing multicenter consortia in liver disease in Latin America: Challenges and opportunities.

P2860

Q39357015-C14C9ADE-3154-4C61-8E2F-42CBD5433E75

P2860

Ombitasvir/paritaprevir/ritonavir/dasabuvir ± ribavirin is safe and effective in HCV-infected patients in a real-life cohort from Latin America.

Item

http://www.wikidata.org/entity/Q38859560

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Ombitasvir/paritaprevir/ritona ...... ife cohort from Latin America.

@en

type

Item

label

Ombitasvir/paritaprevir/ritona ...... ife cohort from Latin America.

@en

prefLabel

Ombitasvir/paritaprevir/ritona ...... ife cohort from Latin America.

@en

P1476

Ombitasvir/paritaprevir/ritona ...... life cohort from Latin America

@en

P2093

Adriana Varón

http://www.w3.org/2001/XMLSchema#string

Alberto Muñoz

http://www.w3.org/2001/XMLSchema#string

Alejandro A Soza

http://www.w3.org/2001/XMLSchema#string

Alejandro Ferrada

http://www.w3.org/2001/XMLSchema#string

Andres E Ruf

http://www.w3.org/2001/XMLSchema#string

Claudia Vujacich

http://www.w3.org/2001/XMLSchema#string

Daniel Coccozella

http://www.w3.org/2001/XMLSchema#string

Daniel Poncino

http://www.w3.org/2001/XMLSchema#string

Edmundo Aravena

http://www.w3.org/2001/XMLSchema#string

Fernando Gruz

http://www.w3.org/2001/XMLSchema#string

P2860

Validity and Reliability of the US National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)

Disease progression in chronic hepatitis C: modifiable and nonmodifiable factors.

Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post-liver transplantation recurrence

Response to therapy with pegylated interferon and ribavirin for chronic hepatitis C in hispanics compared to non-Hispanic whites.

Trends and projections of hepatitis C virus epidemiology in Latin America.

Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin for hepatitis C in patients co-infected with HIV-1: a randomized trial.

Real-world effectiveness and safety of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin in hepatitis C: AMBER study.

Efficacy of Direct-Acting Antiviral Combination for Patients With Hepatitis C Virus Genotype 1 Infection and Severe Renal Impairment or End-Stage Renal Disease.

Effectiveness and Safety of Ombitasvir-Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin for HCV Genotype 1 Infection for 12 Weeks Under Routine Clinical Practice.

Sustained virologic response of 100% in HCV genotype 1b patients with cirrhosis receiving ombitasvir/paritaprevir/r and dasabuvir for 12weeks.

P304

1590-1596

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/JMV.24816

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

E Ridruejo

Manuel Mendizabal

P577

2017-06-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28370222

http://www.w3.org/2001/XMLSchema#string

P921

ombitasvir

Ombitasvir/paritaprevir/ritonavir/dasabuvir ± ribavirin is safe and effective in HCV-infected patients in a real-life cohort from Latin America.

about

P2860

P2860

Ombitasvir/paritaprevir/ritonavir/dasabuvir ± ribavirin is safe and effective in HCV-infected patients in a real-life cohort from Latin America.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P921